Recombinant silk producer AMSilk raises 29m
AMSilk GmbH has closed a Series C financing at 29m to accelerate and expand commercialisation of its microbially produced silk fibres.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
SARS-CoV-2-antibodies may promote severe COVID-19
/in News/by Thomas GabrielczykImmunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
/in News/by Thomas GabrielczykInternational life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
USA supports to temporarily waive IP of COVID-19 vaccines
/in News/by Thomas GabrielczykThe Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Swiss Oculis SA raises $57m in Series C
/in News/by Thomas GabrielczykTopical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
Mogrifiy completes Series A financing round
/in News/by Thomas GabrielczykCell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
COVID-19 vaccine for poor countries
/in News/by Thomas GabrielczykModerna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.
ADCendo ApS raises 51m in Series A financing
/in News/by Thomas GabrielczykDanish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.
DNA Script bags DARPA funding
/in News/by Thomas GabrielczykDNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic.
First malaria vaccine meets WHO efficacy criteria
/in News/by Thomas GabrielczykResearchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso.